Press Release: Sanofi and Regeneron expand global Alliance with multiple next-generation, long-acting immunology antibodies

Regeneron and Sanofi expanded their 20-year antibody alliance to co-develop and co-commercialize four new long-acting immunology antibodies targeting IL-13, IL-4xIL-13, IL-4 and IL-4Rα. Regeneron receives a $1 billion upfront payment with up to $7 billion in additional milestones; the companies share development and commercialization costs and split profits 50:50 globally, with Regeneron leading R&D and Sanofi leading commercialization. Lead asset REGN20423, a long-acting IL-13 antibody, is in a phase 1 study for atopic dermatitis, with the other three antibodies expected to enter the clinic in 2027; Regeneron also holds an option to add Sanofi's lunsekimig after its phase 3 COPD studies.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.